Newron Pharmaceuticals S.p.A. (NWPHF)
OTCMKTS · Delayed Price · Currency is USD
12.00
+0.60 (5.26%)
May 15, 2024, 9:30 AM EDT
Newron Pharmaceuticals Revenue
Newron Pharmaceuticals had revenue of 11.90M EUR in the half year ending June 30, 2025, with 116.56% growth. This brings the company's revenue in the last twelve months to 59.88M, up 759.12% year-over-year. In the year 2024, Newron Pharmaceuticals had annual revenue of 51.39M with 467.41% growth.
Revenue (ttm)
59.88M EUR
Revenue Growth
+759.12%
P/S Ratio
5.01
Revenue / Employee
2.72M EUR
Employees
22
Market Cap
352.53M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.39M | 42.33M | 467.41% |
Dec 31, 2023 | 9.06M | 2.96M | 48.62% |
Dec 31, 2022 | 6.09M | 332.00K | 5.76% |
Dec 31, 2021 | 5.76M | 504.00K | 9.59% |
Dec 31, 2020 | 5.26M | -1.78M | -25.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |
Newron Pharmaceuticals News
- 21 days ago - Newron presents H1 2025 results and provides business update - Business Wire
- 4 weeks ago - Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP) - Business Wire
- 2 months ago - Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS) - Business Wire
- 2 months ago - Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction - Business Wire
- 3 months ago - Edison Issues Report on Newron Pharmaceuticals (NWRN) - Newsfile Corp
- 5 months ago - Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS) - Business Wire
- 6 months ago - Newron Presents 2024 Financial Results and Provides 2025 Outlook - Business Wire
- 7 months ago - Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference - Business Wire